Navigation Links
Questcor Pharmaceuticals Issues Statement
Date:1/11/2012

ANAHEIM, Calif., Jan. 11, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced it became aware that an investor blog is preparing to issue a report regarding the Company's marketing and business practices.  Questcor issued the following statement:

The Company believes that its marketing and business practices are consistent with regulatory requirements and industry standard practices.  Questcor markets H.P. Acthar® Gel for the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age.  The Company maintains a compliance program, which is led by an experienced compliance officer and includes the active participation of Questcor's executive management team.  Questcor attributes its success to the ability of Acthar to potentially address the unmet medical need associated with MS exacerbations and nephrotic syndrome.  The Company is committed to providing access to Acthar to patients who need it, and marketing Acthar in accordance with regulatory requirements and industry standard practices.  Questcor plans to speak with the publication to discuss the Company and its marketing and business practices.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information, please visit www.questcor.com.

 

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Solid Fourth Quarter Results
2. Questcor to Discuss Results From FDA Panel Meeting
3. Trading Halted Today in Questcor Pharmaceuticals Common Stock
4. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
5. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor to Present at UBS Global Life Sciences Conference
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... June 1, 2017 Nutriceutical Holdings (NH), parent ... Solutions (VRS), and KD Pharma Group have decided to ... by KD Pharma Group. KD Pharma Group will become ... to acquire the entire company. "We believe ... are committed to growing the NH companies by providing ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
Breaking Medicine Technology:
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... , ... June 24, 2017 , ... Studies show evidence ... reduce the risk of visual loss in these patients. , But how often do ... or smoking cessation to patients at risk of or with early symptoms of AMD? ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
Breaking Medicine News(10 mins):